Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience (NASDAQ: DARE) announced positive interim Phase 3 results for Ovaprene®, their investigational hormone-free monthly intravaginal contraceptive. The Data Safety Monitoring Board recommended continuing the study without modifications after reviewing safety data.
Key interim findings show a 9% pregnancy rate among treated women, aligning with pre-pivotal study expectations. While 17% of participants discontinued due to vaginal odor, no serious safety concerns were identified. The ongoing multicenter study targets 250 participants for 12-month use evaluation.
Bayer holds rights to obtain exclusive U.S. commercialization through a $20 million payment post-trial completion, with potential earnings of up to $310 million in commercial milestones plus double-digit tiered royalties.
Daré Bioscience (NASDAQ: DARE) has received a $6 million non-dilutive grant installment for developing DARE-LARC1, bringing the total received to $37.8 million of a $49 million commitment. DARE-LARC1 is a preclinical-stage long-acting reversible contraceptive utilizing their intelligent drug delivery system (DARE-IDDS) platform.
The DARE-IDDS platform, originally developed at MIT, features wireless control, precision dosing, and extended duration capabilities. The technology can deliver hundreds of individualized doses over months or years without recharging. Beyond contraception, the platform shows potential applications in obesity, diabetes, and other chronic conditions requiring precise, long-term dosing.
The company is actively exploring strategic partnerships to expand the platform's use beyond reproductive health, with $11.2 million in additional non-dilutive funding available upon achieving specific milestones.
Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has scheduled its Q1 2025 financial results and company update conference call for May 13, 2025, at 4:30 p.m. Eastern Time. Investors can access the call via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 3461324. A live webcast will be available on the company's investor relations website, with replay access until May 27, 2025.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will deliver a keynote address at the Fierce Pharma Engage summit on April 29, 2025. The presentation, titled 'Breaking Barriers, Building Access: Communicating Bold Moves in Women's Health Innovation,' will focus on the company's expanded business strategy incorporating 503B compounding.
The company recently unveiled a dual-path approach for its proprietary Sildenafil Cream formulation, targeting prescription availability in Q4 2025. Daré's portfolio includes XACIATO™, an FDA-approved bacterial vaginosis treatment licensed to Organon, and several first-in-category candidates:
- Ovaprene® - hormone-free monthly contraceptive (licensed to Bayer)
- Sildenafil Cream, 3.6% - for female sexual arousal disorder
- DARE-HRT1 - bio-identical hormone therapy ring
Daré Bioscience (NASDAQ: DARE) has announced its expanded business strategy featuring a dual-path approach for its proprietary Sildenafil Cream formulation, with plans to make it available via prescription in Q4 2025. The company's President and CEO, Sabrina Martucci Johnson, will present these developments at the Jones Healthcare and Technology Innovation Conference on April 9th, 2025.
The strategy includes utilizing Section 503B compounding to expedite market access for select Daré proprietary formulations. The company is also exploring bringing consumer health products to market without prescription requirements. Additional strategic partnerships and timing updates are expected this quarter.
The presentation will be accessible via webcast at 1:00 p.m. PT, with a replay available until April 23, 2025, through the company's investor relations website.
Daré Bioscience (NASDAQ: DARE) reported its full year 2024 financial results and announced plans to make its proprietary Sildenafil Cream available via prescription through 503B compounding in Q4 2025, expecting to generate revenue and cash flow. The company ended 2024 with $15.7 million in cash and a working capital deficit of $3.2 million.
Financial highlights show reduced expenses, with G&A costs down 24% to $9.2 million and R&D expenses decreased 34% to $14.2 million compared to the previous year. Key pipeline developments include the ongoing Ovaprene® Phase 3 contraceptive study, with approximately 125 women expected to complete six months of use by Q2 2025, supported by a $10.7 million non-dilutive grant.
The company is pursuing a dual-path approach for select proprietary formulations, including both FDA approval and 503B framework distribution. Daré plans to invest less than $1 million to support the Sildenafil Cream 503B initiative and expects to provide strategic partnership updates in Q2 2025.
Daré Bioscience (NASDAQ: DARE), a women's health innovation company, has scheduled its full year 2024 financial results conference call and webcast for March 31, 2025, at 4:30 p.m. Eastern Time. The presentation will include both financial performance review and company updates.
Participants can join via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 9767621. A live webcast will be available through the Investors section of Daré's website. The webcast recording will remain accessible for replay until April 14, 2025.